ERR2598171
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 4
- umap1_2d
- -2.155052221
- umap2_2d
- -1.060692233
- umap1_3d
- -3.962865437
- umap2_3d
- 3.362068346
- umap3_3d
- -1.435085835
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.650
- G2M_CHECKPOINT+0.590
- MYC_TARGETS_V1+0.550
- MYC_TARGETS_V2+0.530
- ANGIOGENESIS+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- TGF_BETA_SIGNALING+0.450
- WNT_BETA_CATENIN_SIGNALING+0.420
- MITOTIC_SPINDLE+0.360
- ANDROGEN_RESPONSE+0.330
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.430
- INTERFERON_ALPHA_RESPONSE-0.270
- INTERFERON_GAMMA_RESPONSE-0.240
- ADIPOGENESIS-0.230
- PEROXISOME-0.230
- BILE_ACID_METABOLISM-0.170
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.170
- XENOBIOTIC_METABOLISM-0.140
- COMPLEMENT-0.100
- FATTY_ACID_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598166 | fetal | fetal | 0.961 |
| 2 | ERR2598170 | fetal | fetal | 0.942 |
| 3 | ERR2598184 | fetal | fetal | 0.936 |
| 4 | ERR2598197 | fetal | fetal | 0.893 |
| 5 | ERR2598180 | fetal | fetal | 0.884 |
| 6 | ERR2598164 | fetal | fetal | 0.854 |
| 7 | ERR2598207 | fetal | fetal | 0.853 |
| 8 | ERR2598165 | fetal | fetal | 0.852 |
| 9 | ERR2598181 | fetal | fetal | 0.839 |
| 10 | ERR2598169 | fetal | fetal | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.650 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.470 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |